Compare ARQT & VIRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARQT | VIRT |
|---|---|---|
| Founded | 2016 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.8B |
| IPO Year | 2020 | 2015 |
| Metric | ARQT | VIRT |
|---|---|---|
| Price | $28.33 | $33.87 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 7 |
| Target Price | $24.83 | ★ $41.43 |
| AVG Volume (30 Days) | ★ 2.0M | 906.6K |
| Earning Date | 10-28-2025 | 01-28-2026 |
| Dividend Yield | N/A | ★ 2.84% |
| EPS Growth | N/A | ★ 132.69 |
| EPS | N/A | ★ 4.62 |
| Revenue | $317,929,000.00 | ★ $2,694,104,000.00 |
| Revenue This Year | $85.51 | N/A |
| Revenue Next Year | $30.74 | N/A |
| P/E Ratio | ★ N/A | $7.33 |
| Revenue Growth | ★ 129.21 | 41.05 |
| 52 Week Low | $11.13 | $31.89 |
| 52 Week High | $31.77 | $45.77 |
| Indicator | ARQT | VIRT |
|---|---|---|
| Relative Strength Index (RSI) | 51.12 | 43.65 |
| Support Level | $27.55 | $33.30 |
| Resistance Level | $28.90 | $34.52 |
| Average True Range (ATR) | 1.15 | 0.86 |
| MACD | -0.55 | -0.16 |
| Stochastic Oscillator | 18.58 | 29.59 |
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
Virtu Financial Inc is a financial firm that leverages technology to deliver liquidity to the world-wide markets and transparent trading solutions to its clients. The company's operating segment includes Market Making; and Execution Services. The non-operating segment of the company includes the Corporate segment. The company generates maximum revenue from the market-making segment. The Market Making segment principally consists of market-making in the cash, futures, and options markets across equities, options, fixed income, currencies, and commodities. Geographically, it derives a majority of its revenue from the United States and also has a presence in Ireland and Other Countries.